^
Association details:
| Biomarker: | AXL elevation + GAS6 elevation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Cabometyx (cabozantinib tablet) (Multi-tyrosine kinase inhibitor) + batiraxcept (AVB-500) (AXL inhibitor, GAS6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC).
Published date:
02/13/2023
Excerpt:
Key eligibility criteria include previously treated ccRCC pts, excluding prior cabozantinib. Objectives were to determine the safety of batiraxcept plus cabozantinib....Twenty (77%) pts had high baseline sAXL/GAS6 levels; ORR was 55% (11/20) with mPFS of 9.3 mo, compared to 0% ORR and mPFS 6.4 mo in the low sAXL/GAS6 pts….Batiraxcept was well tolerated when combined with cabozantinib. No new safety signals were noted. Efficacy for the combination is encouraging compared to historical cabozantinib monotherapy data. Higher GAS6 levels were predictive for treatment response.
DOI:
10.1200/JCO.2023.41.6_suppl.666
Trial ID:
